Paper Details

  1. Home
  2. Paper Details

Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.

Author: AsseburgChristian, BriggsAndrew, CumminsEwen, FenwickElisabeth, MorrisJames, PunekarYogesh Suresh, ShoreEmily

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Infliximab was a cost-effective treatment option for active and progressive psoriatic arthritis. In a decision analytic model, infliximab was associated with a significant reduction in Health Assessment Questionnaire score and a cost-effectiveness ratio well within the National Institute for Health and Clinical Excellence threshold.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Despite its proven efficacy, infliximab is often considered to be an expensive treatment for patients with psoriatic arthritis. OBJECTIVES: To estimate the cost-effectiveness of infliximab among patients with active and progressive psoriatic arthritis. METHODS: A decision analytic mode...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jval.2010.10.016

データ提供：米国国立医学図書館（NLM）

Infliximab: A Cost-Effective Treatment for Psoriatic Arthritis

The world of [rheumatology] is constantly searching for effective and affordable treatments for [psoriatic arthritis], a debilitating condition that impacts joints and skin. This study explores the [cost-effectiveness] of [infliximab], a [tumor necrosis factor α inhibitor], in managing [active and progressive psoriatic arthritis]. It's like navigating a desert landscape, seeking to find a balance between the benefits of treatment and the resources needed to provide it.

A Cost-Effective Solution for Psoriatic Arthritis

The study employs a [decision analytic model] to simulate the progression of [psoriatic arthritis] in patients receiving [infliximab maintenance treatment]. The researchers compared the outcomes of infliximab with [palliative care], which includes [nonbiologic disease-modifying antirheumatic drugs]. Their analysis reveals that [infliximab] is a [cost-effective treatment option] compared to [palliative care], offering significant benefits in terms of [Health Assessment Questionnaire scores] and [quality-adjusted life years]. This is like discovering a valuable oasis that provides both sustenance and a safe haven for travelers facing the challenges of psoriatic arthritis.

Navigating the Landscape of Treatment Options

The study also examines the [cost-effectiveness] of other [tumor necrosis factor α inhibitors], finding that [etanercept, adalimumab, and infliximab] are all [cost-effective] compared to [palliative care]. This information is crucial for healthcare providers and policy makers, as it provides a framework for making informed decisions about treatment options for patients with [psoriatic arthritis]. It's like having a map of the desert, revealing different pathways to optimal outcomes.

Dr.Camel's Conclusion

This cost-effectiveness analysis provides valuable insights into the use of [infliximab] for [psoriatic arthritis]. The findings highlight the importance of balancing efficacy, cost, and individual patient needs when selecting treatment options. It's a reminder that the desert of [rheumatology] research is always evolving, with new discoveries constantly shaping the landscape of patient care.

Date :
  1. Date Completed 2011-03-17
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

21211482

DOI: Digital Object Identifier

10.1016/j.jval.2010.10.016

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.